Eloralintide: Dosage, Protocol, and Research Guide
Selective long-acting amylin receptor agonist in clinical development for obesity
Mechanism
Preferentially activates the amylin 1 receptor (AMY1R) over calcitonin and AMY3 receptors, producing satiety and slowed gastric emptying without GLP-1 receptor involvement. A C20 fatty diacid conjugated at lysine-26 drives albumin binding, extending the half-life to roughly two weeks and supporting once-weekly dosing.
Protocol at a glance
| Starting dose | 1mg |
|---|---|
| Maintenance dose | 3-9mg |
| Maximum dose | 9mg |
| Frequency | Once weekly |
| Typical duration | Ongoing therapy |
| Route | Subcutaneous |
| Injection site | Abdomen, thigh, or upper arm |
| Timing | Any time of day, same day each week |
Titration schedule
| Week | Dose | Notes |
|---|---|---|
| 1 | 1mg | Initial dose for 4 weeks |
| 5 | 3mg | First increase |
| 9 | 6mg | Standard maintenance |
| 13 | 9mg | Maximum dose studied |
Side effects
- Nausea
- Fatigue
- Vomiting
- Decreased appetite
- Injection site reactions
Contraindications
- Gastroparesis
- Hypoglycemia unawareness
Protocol notes
- Amylin pathway only — does not act on GLP-1 receptors
- Phase 2 (48 weeks) reported 9.5% to 20.1% mean weight loss vs 0.4% on placebo
- Nausea and fatigue were markedly lower in the slow-escalation arms
- Investigational (Eli Lilly, LY3841136) — not FDA-approved
Research references
Frequently asked questions
What is eloralintide?
Eloralintide (LY3841136) is an investigational selective amylin receptor agonist from Eli Lilly, studied for obesity. It preferentially activates the amylin 1 receptor (AMY1R) and does not act on GLP-1 receptors. For research purposes only — not FDA-approved for human use.
How is eloralintide dosed?
Phase 2 used once-weekly subcutaneous dosing at 1mg, 3mg, 6mg or 9mg, plus escalation arms stepping 3mg to 6mg to 9mg. A gradual ramp — roughly four weeks per step — was associated with substantially better tolerability than starting at a high fixed dose. Confirm any protocol with a licensed physician.
How much weight loss did eloralintide produce in trials?
In the 48-week phase 2 trial of 263 adults, mean weight loss ranged from about 9.5% at 1mg to 20.1% at 9mg, versus 0.4% on placebo. The 9mg and 6/9mg escalation cohorts both reached roughly 20%.
What is eloralintide's half-life?
Roughly 13 to 15 days, driven by a C20 fatty diacid at lysine-26 that binds albumin. That supports once-weekly dosing but also means levels keep climbing for several weeks after a dose increase before reaching steady state.
How is eloralintide different from semaglutide or tirzepatide?
Completely different receptor target. Semaglutide is a GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist; eloralintide acts only on amylin receptors, reproducing the satiety signal amylin normally provides alongside insulin. Because the pathways do not overlap, amylin agonists are also being investigated alongside incretin therapy rather than purely as substitutes.
How does eloralintide compare to cagrilintide?
Both are long-acting amylin analogs, but cagrilintide (Novo Nordisk) is a less selective amylin/calcitonin receptor agonist with a roughly 7-day half-life, largely developed as a combination partner for semaglutide (CagriSema). Eloralintide is AMY1R-selective, has a substantially longer half-life (~13-15 days), and showed up to 20% weight loss as monotherapy in phase 2.
What are the side effects of eloralintide?
Most commonly nausea and fatigue, both dose- and escalation-rate dependent. Nausea was 11-13% at 1-3mg (comparable to placebo at 14%) but 64% in the fixed 6mg arm; fatigue ranged from 0% to 46%. Events were mainly mild to moderate, and slower escalation lowered incidence. Vomiting, decreased appetite, and injection site reactions were also reported.
Is eloralintide FDA-approved?
No. Eloralintide is an investigational compound that has completed phase 2 trials. It is not approved by the FDA or any other regulatory authority and is not available by prescription. For research purposes only — consult a licensed physician before use.
More GLP-1 & Weight Loss peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.